ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2025-8-1-29-35ojrdrt-415Research ArticleЯДЕРНАЯ МЕДИЦИНАNUCLEAR MEDICINEЭТ/КТ с 68Ga-FAPI и 18F-FDG в оценке метастатического поражения регионарных лимфоузлов при раке желудкаPET/CT with 68Ga-FAPI and 18F-FDG in the Detection of Metastases in Regional Lymph Nodes in Gastric Cancerhttps://orcid.org/0009-0009-0819-3891БелкинЕ. В.BelkinE. V.

Белкин Егор Владимирович

115478 Москва, Каширское шоссе, 24

Egor V. Belkin

24 Kashirskoye Shosse, Moscow, 115478

ega.belkin@yandex.ruhttps://orcid.org/0000-0001-7226-5129ТулинП. Е.TulinP. E.

115478 Москва, Каширское шоссе, 24

Pavel E. Tulin

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0002-7045-0977Абу-ХайдарО. Б.Abu-KhaydarO. B.

115478 Москва, Каширское шоссе, 24

Omar B. Abu-Khaydar

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0003-1030-1686СкрипачевИ. А.SkripachevI. A.

115478 Москва, Каширское шоссе, 24

Ivan A. Skripachev

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0009-0001-6694-9564ФилимоновА. В.FilimonovA. V.

115478 Москва, Каширское шоссе, 24

Alexander V. Filimonov

24 Kashirskoye Shosse, Moscow, 115478

Национальный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation202503042025812935Copyright © Белкин Е.В., Тулин П.Е., Абу-Хайдар О.Б., Скрипачев И.А., Филимонов А.В., 20252025Белкин Е.В., Тулин П.Е., Абу-Хайдар О.Б., Скрипачев И.А., Филимонов А.В.Belkin E.V., Tulin P.E., Abu-Khaydar O.B., Skripachev I.A., Filimonov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/415Цель

Цель: Определить диагностическую эффективность ПЭТ/КТ с 68Ga-FAPI при раке желудка.

Материал и методы

Материал и методы: В исследование включены 42 пациента с верифицированным раком желудка. Всем пациентам проведены ПЭТ/КТ с 68Ga-FAPI и ПЭТ/КТ с 18F-FDG. Сравнивалась диагностическая точность методов по параметрам чувствительности и специфичности в отношении выявления метастатического поражения регионарных лимфатических узлов. Оценка данных проводилась на основании гистологически верифицированного заболевания и данных клинического наблюдения.

Заключение

Заключение: ПЭТ/КТ с 68Ga-FAPI является более эффективным методом диагностики для определения метастазов в регионарных лимфатических узлах, чем ПЭТ/КТ с 18F-FDG. Полученные результаты свидетельствуют о перспективности использования ПЭТ/КТ с 68Ga-FAPI в клинической практике для более точной диагностики и выбора тактики лечения при раке желудка.

Purpose

Purpose: To determine the diagnostic effectiveness of PET/CT with 68Ga-FAPI in gastric cancer.

Matreial and Methods

Matreial and Methods:The study included 42 patients with histologically confirmed gastric cancer. All patients underwent PET/CT with 68Ga-FAPI and PET/CT with 18F-FDG. The diagnostic accuracy of the methods was compared based on sensitivity and specificity parameters in detecting metastatic involvement of regional lymph nodes. Data assessment was conducted based on histologically verified disease and clinical follow-up data.

Results

Results: PET/CT with 68Ga-FAPI is a more effective diagnostic method for detecting metastases in regional lymph nodes compared to PET/CT with 18F-FDG. Our results support the clinical potential of PET/CT with 68Ga-FAPI for improved diagnosis and treatment planning in gastric cancer.

рак желудкаПЭТпозитронная эмиссионная томография68Ga-FAPI18F-FDGgastric cancerPETpositron emission tomography68Ga-FAPI18F-FluorodeoxyglucoseReferencesBray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834.Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-29. https://doi.org/10.1053/j.gastro.2017.04.022.Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-29. https://doi.org/10.1053/j.gastro.2017.04.022.Kim H, Hwang Y, Sung H, et al. Effectiveness of gastric cancer screening on gastric cancer incidence and mortality in a community-based prospective cohort. Cancer Res Treat. 2018;50(2):582-89. https://doi.org/10.4143/crt.2017.048.Kim H, Hwang Y, Sung H, et al. Effectiveness of gastric cancer screening on gastric cancer incidence and mortality in a community-based prospective cohort. Cancer Res Treat. 2018;50(2):582-89. https://doi.org/10.4143/crt.2017.048.Hamashima C, Ogoshi K, Okamoto M, et al. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013;8(11):e79088. https://doi.org/10.1371/journal.pone.0079088.Hamashima C, Ogoshi K, Okamoto M, et al. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013;8(11):e79088. https://doi.org/10.1371/journal.pone.0079088.Jun JK, Choi KS, Lee H-Y, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017;152(6):1319-28.e7. https://doi.org/10.1053/j.gastro.2017.01.029.Jun JK, Choi KS, Lee H-Y, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017;152(6):1319-28.e7. https://doi.org/10.1053/j.gastro.2017.01.029.Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020;69(5):823-9. https://doi.org/10.1136/gutjnl-2019-320234.Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020;69(5):823-9. https://doi.org/10.1136/gutjnl-2019-320234.Бесова НС, Болотина ЛВ, Гамаюнов СВ и др. Рак желудка. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли. 2024;14(3s2):241-62. https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-13.Бесова НС, Болотина ЛВ, Гамаюнов СВ и др. Рак желудка. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли. 2024;14(3s2):241-62. https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-13.Клинические рекомендации. Рак желудка. Клинические рекомендации Ассоциации онкологов России и Российского общества клинической онкологии. 2020. AOP (Internet). https://oncology-association.ruКлинические рекомендации. Рак желудка. Клинические рекомендации Ассоциации онкологов России и Российского общества клинической онкологии. 2020. AOP (Internet). https://oncology-association.ruMuto M, Saito S, Muto M, et al. Effect of adding X-ray examination to endoscopy in the assessment of the invasion depth of early gastric cancer. Nihon Shokakibyo Gakkai Zasshi. 2019;116(6):506-14. https://doi.org/10.11405/nisshoshi.116.506.Muto M, Saito S, Muto M, et al. Effect of adding X-ray examination to endoscopy in the assessment of the invasion depth of early gastric cancer. Nihon Shokakibyo Gakkai Zasshi. 2019;116(6):506-14. https://doi.org/10.11405/nisshoshi.116.506.Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):19-33. https://doi.org/10.1093/annonc/mdy502.Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):19-33. https://doi.org/10.1093/annonc/mdy502.Seo N, Lim JS, Cho A. Radiologic Diagnosis (CT, MRI, PET-CT). In: Noh, S., Hyung, W. (eds). Surgery for Gastric Cancer. Berlin: Sp ring er. 20 19:67-86. https://doi.org/10.1007/978-3-662-45583-8ͺ4.Seo N, Lim JS, Cho A. Radiologic Diagnosis (CT, MRI, PET-CT). In: Noh, S., Hyung, W. (eds). Surgery for Gastric Cancer. Berlin: Sp ring er. 20 19:67-86. https://doi.org/10.1007/978-3-662-45583-8ͺ4.Wang Y, Liu W, Yu Y, et al. CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer. Eur Radiol. 2020;30(2):976-86. https://doi.org/10.1007/s00330-019-06398-z.Wang Y, Liu W, Yu Y, et al. CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer. Eur Radiol. 2020;30(2):976-86. https://doi.org/10.1007/s00330-019-06398-z.National Comprehensive Cancer Network, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guide-linesΠ): Gastric Cancer. Version 5.2024. www.nccn.org.National Comprehensive Cancer Network, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guide-linesΠ): Gastric Cancer. Version 5.2024. www.nccn.org.Kobayashi S, Ogura M, Suzawa N, et al. 18F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis. BMC Med Imaging. 2016;16(1):58. https://doi.org/10.1186/s12880-016-0161-9.Kobayashi S, Ogura M, Suzawa N, et al. 18F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis. BMC Med Imaging. 2016;16(1):58. https://doi.org/10.1186/s12880-016-0161-9.Yin C, Gao B, Yang J, et al. Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer. Med Sci Monit Basic Res. 2020;26:e920778. https://doi.org/10.12659/MSMBR.920778.Yin C, Gao B, Yang J, et al. Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer. Med Sci Monit Basic Res. 2020;26:e920778. https://doi.org/10.12659/MSMBR.920778.Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5-6):454-63. https://doi.org/10.1002/prca.201300095.Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5-6):454-63. https://doi.org/10.1002/prca.201300095.Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances. Diagnostics (Basel). 2022;12(8):1958. https://doi.org/10.3390/diagnostics12081958.Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances. Diagnostics (Basel). 2022;12(8):1958. https://doi.org/10.3390/diagnostics12081958.Yin C, Shao F, Gai Y, et al. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022;63(1):81-8. https://doi.org/10.2967/jnumed.120.258467.Yin C, Shao F, Gai Y, et al. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022;63(1):81-8. https://doi.org/10.2967/jnumed.120.258467.Ruan D, Zhao L, Cai J, et al. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. Theranostics. 2023;13(13):4694-10. https://doi.org/10.7150/thno.88335.Ruan D, Zhao L, Cai J, et al. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. Theranostics. 2023;13(13):4694-10. https://doi.org/10.7150/thno.88335.

The authors declare that there are no conflicts of interest present.